A new bipartisan report outlines the nation's vulnerabilities to growing biological threats and provides recommendations on how the United States can defend itself against biological weapons and infectious diseases.
The 92-page report, "A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts, was compiled by the Blue Ribbon Study Panel on Biodefense.
The panel spent more than a year reviewing the country's biodefense activities and "identified substantial achievements, but also found serious gaps that leave the homeland vulnerable," wrote panel co-chairs Tom Ridge (R-Pa.), former governor and homeland security, and Sen. Joseph Lieberman (I-Conn.), in an opinion piece published by Philly.com.
The gaps include last year's Ebola outbreak, which led to confusion over roles and responsibilities once the first patient was diagnosed in the United States. It also was apparent during a massive outbreak of avian influenza in the Midwest poultry industry, they wrote.
The problem, they said, is due to lack of leadership that led to insufficient coordination across the federal government; inadequate focus on collaboration with and support for nonfederal stakeholders who handle critical activities such as surveillance and response; and a risk aversion that stifles the innovations required to solve challenging technological and governance problems.
"These symptoms are not abstract," Ridge and Lieberman wrote. "If they were rectified, hospitals would have the guidance they need to handle Ebola."
They called for the vice president to serve as the leader who can take the necessary steps to create a biodefense coordination council and develop a national strategy for biodefense.
The report also makes 33 recommendations to fix the vulnerabilities. Here are 10 that relate directly to the healthcare industry:
- Prioritize and align investments in medical countermeasures among all federal stakeholders
- Provide emergency service providers with the resources they need to keep themselves and their families safe
- Redouble efforts to share information with state, local, territorial and tribal partners
- Fund the Public Health Emergency Preparedness cooperative agreement at no less than authorized levels
- Establish and use a standard process to develop and issue clinical infection control guidance for biological events
- Minimize redirection of Hospital Preparedness Program funds
- Provide the financial incentives hospitals need to prepare for biological events
- Establish a biodefense hospital system
- Provide incentives for the development of rapid point-of-care diagnostics
- Lead the way toward establishing a functional and agile global public health response apparatus